A Study With SAGE-547 for Super-Refractory Status Epilepticus
Status:
Completed
Trial end date:
2017-08-11
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled trial, designed to evaluate the
efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to subjects
in Super-Refractory Status Epilepticus (SRSE).